WHO ICTRP trial
Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in…
CTIS2023-509047-26-00 · EU Clinical Trials Information System · Recruiting
Key facts
| Trial ID | CTIS2023-509047-26-00 |
|---|---|
| Public title | Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors |
| Scientific title | - 20220028 |
| Primary sponsor | Amgen Inc. |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): Yes Therapeutic exploratory (Phase II): No Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): No |
| Countries | United States;Taiwan;Japan;Korea, Republic of;Australia;Canada;Switzerland;France;Spain;Poland;Netherlands |
| Conditions | Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive… |
| Registration date | Jan 31, 2024 |
| Target size | 485 |
| Secondary IDs | NCT06131398;U1111-1301-0488 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: